Brentuximab vedotin with chemotherapy for Stage 3/4 classical Hodgkin lymphoma (cHL): 4-year update of the ECHELON-1 study Meeting Abstract
| Authors: | Bartlett, N. L.; Straus, D. J.; Dlugosz-Danecka, M.; Alekseev, S.; Illes, A.; Lech-Maranda, E.; Feldman, T. A.; Smolewski, P.; Savage, K. J.; Walewski, J.; Ramchandren, R.; Zinzani, P. L.; Hutchings, M.; Connors, J. M.; Radford, J.; Munoz, J.; Kim, W. S.; Advani, R. H.; Ansell, S. M.; Younes, A.; Gallamini, A.; Miao, H.; Liu, R.; Fenton, K.; Forero-Torres, A.; Picardi, M. |
| Abstract Title: | Brentuximab vedotin with chemotherapy for Stage 3/4 classical Hodgkin lymphoma (cHL): 4-year update of the ECHELON-1 study |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164602049 |
| DOI: | 10.1182/blood-2019-124116 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4026 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work